Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab + teclistamab in relapsed or refractory multiple myeloma
2023-503439-16-00Phase 2Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 6
01
Overview
Phase 2, open-label trial of talquetamab and teclistamab in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting toxicities, Adverse events and serious adverse events and 1 more. Planned start Dec 2020; status: authorised.
02
Drugs
talquetamabteclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-503439-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503439-16-00.